期刊文献+

尿毒症腹膜透析患者血脂变化的临床观察 被引量:3

Clinical Observation on the Change of Blood Lipids in Uremia Patients with Peritoneal Dialysis
暂未订购
导出
摘要 【目的】观察腹膜透析对尿毒症患者血脂的影响。【方法】尿毒症患者42例,对照组40例,分别在腹膜透析前、透析后检测血脂水平。【结果】尿毒症患者血清胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A(ApoA)较健康人的血脂水平明显升高(P〈0.05);透析后患者血清TG、LDL-C、Apo A较透析前明显升高(P〈0.05)。【结论】尿毒症患者透析前存在血脂异常,腹膜透析可能会加重患者的高脂血症。 [Objective] To observe the effect of peritoneal dialysis on blood lipids in uremia patients. [Methods] Blood lipids in 42 cases of uremia and 40 controls were determined before and after peritoneal dialysis. [Results] Compared with the healthy controls, serum cholesterol(TC), triglyeride(TG), low density lipoprotein cholesterol(LDI-C) and apolipoprotein A(ApoA) in uremia patients increased significantly( P 〈 0. 05). Compared with before peritoneal dialysis, serum TG, LDL-C and ApoA in patients after peritoneal dialysis increased significantly( P 〈0.05). [Conclusion] Uremia patients have dyslipidemia before dialysis. Perito neal dialysis maybe aggravates the hyperlipidemia in uremia patients.
作者 唐文庄
出处 《医学临床研究》 CAS 2010年第10期1848-1849,共2页 Journal of Clinical Research
关键词 尿毒症/治疗 腹膜透析 脂类/血液 uremia/TH peritoneal dialysis lipids/BL
  • 相关文献

参考文献7

二级参考文献37

  • 1汤金娣,徐培桢,邵智萍,尚明花,吴文俊,谢松业,陈国君,徐琴君.透析患者脂蛋白A增高意义的探讨[J].临床泌尿外科杂志,1995,10(3):146-148. 被引量:4
  • 2余学清,沈清端,李惠群,董秀清.不同透析方法对透析病者血浆脂蛋白和载脂蛋白的影响[J].中山医科大学学报,1996,17(2):120-125. 被引量:14
  • 3郑亚莉,吕娟,陈虹,李红霞.肾脏疾病患者血脂及载脂蛋白 A_Ⅰ B_(100) C_Ⅱ的测定及其临床意义探讨[J].宁夏医学院学报,1997,19(1):4-6. 被引量:4
  • 4Sammuelsson O, Attman P, Knight-Gibson C, et al. Complex apolipoprotein B-containing lipoprotein particales are associated with a higher rate of progression of human chronic renal insufficiency.J. Am. Soc. Nephrol. , 1998,9 : 1482-1488.
  • 5Atiman PO,Samuelsson O, Alaupovie P. Lipoprotein metabolism and renal failure. Am. J. Kindey Dis. ,1993,21:573.
  • 6Muntner P,Coresh J,Smlth JC,et al. Plasma lipids and risk of developing renal dysfunction: The Atheroselerosis Risk in Communities study. Kidney Int. ,2000,58:293-301.
  • 7Wheeler DC. Abnormalities of lipoprotein metabolism in CAPD patients, kidney Int. ,1996,55(156):41-46.
  • 8Avram MM,Goldwasser P, Burrell DE et al. The uremic dyslipidemia:A cross-sectionaland longitudinal study. Am. J. Kidney Dis. , 1992,20 : 324- 335.
  • 9Zoccali C,Benedetto FA,Mallamaci F,et al.Inflammation is associated with carotid atherosclerosis in dialysis patients.Creed Investigators.Cardiovascular risk ex tended evaluation in dialysis patients.J Hypertens,2000,18:1207-1213
  • 10Wang AY,Wang M,Woo J,et al.Inflammation,residual kidney function,and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.JAm Soc Nephrol,2004,15:2186-2194

共引文献45

同被引文献45

  • 1王健,肖明英.缬沙坦对CAPD患者残存肾功能的保护作用[J].中国血液净化,2005,4(11):605-606. 被引量:3
  • 2张雪晗,曾正陪,李汉忠,周亚茹,张晶,童安莉,阎朝丽.肾素-血管紧张素-醛固酮系统中不同组分在脂肪组织中的表达[J].中国医学科学院学报,2006,28(6):766-769. 被引量:10
  • 3刘必成,李敏侠.肾素血管紧张素系统阻断剂的肾保护作用[J].中华肾脏病杂志,2007,23(2):129-133. 被引量:41
  • 4钟慧,沙朝晖,崔天蕾,邱红渝,刘芳,秦伟,付平.依贝沙坦对维持性腹膜透析患者残存肾功能的保护作用[J].中华肾脏病杂志,2007,23(7):413-416. 被引量:6
  • 5Li P K,Chow K M,Wong T Y. Effects of angiotensinconverting enzyme inhibitor on residual renal function inpatients receiving peritoneal dialysis.Arandomized,controlled study[J].Annals of Internal Medicine,2003,(02):105-112.
  • 6Fogo A B. The role of angiotensin Ⅱ and plasminogen activator inhibitor-1 in progressive glomerulosclerosis[J].American Journal of Kidney Diseases,2000,(02):179-188.doi:10.1016/S0272-6386(00)70324-6.
  • 7Lavoie J L,Sigmund C D. Minireview:Overview of the renninangiotensin system an endocrine and paracrine system[J].Endocrinology,2003,(06):2179-2183.doi:10.1210/en.2003-0150.
  • 8Li P K,Chow K M. The cost barrier to peritoneal dialysis in the developing world-an Asian perspective[J].Peritoneal Dialysis International,2001,(13):307-313.
  • 9Hainault I,Nebout G,Turban S. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat[J].Am J Physiol Endocrino Metab,2002,(01):E59-E66.
  • 10Okda K,Hirano T,Ran J. Olmesartan medoxomil an angiotensin Ⅱ receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructosefed rats[J].Hypertension,2004,(04):293-299.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部